IRIS

International prognostic scoring system for Waldenstrom macroglobulinemia

GOBBI, PAOLO;MERLINI, GIAMPAOLO
2009-01-01
2009
The Hematology category covers resources concerned with blood, blood-forming tissues, bone marrow, plasma, and transfusions. Coverage also includes resources on specialties such as hemophilia, leukemia, and lymphoma.
BLOOD
sì
WOS:000265846300011
2-s2.0-66149155411
Sì, ma tipo non specificato
Inglese
Internazionale
STAMPA
113
4163
4170
7
Recently, many new drugs have been developed for the treatment of Waldenstrom macroglobulinemia (WM). To optimize the treatment according to the prognosis and to facilitate the comparison of trials, we developed an International Prognostic Scoring System for WM in a series of 587 patients with clearly defined criteria for diagnosis and for initiation of treatment. The median survival after treatment initiation was 87 months. Five adverse covariates were identified: advanced age (> 65 years), hemoglobin less than or equal to 11.5 g/dL, platelet count less than or equal to 100 x 10(9)/L, beta 2-microglobulin more than 3 mg/L, and serum monoclonal protein concentration more than 7.0 g/dL. Low-risk patients (27%) presented with no or 1 of the adverse characteristics and advanced age, intermediate-risk patients (38%) with 2 adverse characteristics or only advanced age, and high-risk patients (35%) with more than 2 adverse characteristics. Five-year survival rates were 87%, 68%, and 36%, respectively (P<.001). The ISSWM retained its prognostic significance in subgroups defined by age, treatment with alkylating agent, and purine analog. Thus, the ISSWM may provide a means to design risk-adapted studies. However, independent validation and new biologic markers may enhance its significance. (Blood. 2009; 113: 4163-4170)
Waldesntrom's macroglobulinemia; prognosis; international scoring system
14
info:eu-repo/semantics/article
262
P., Morel; A., Duhamel; Gobbi, Paolo; M. A., Dimopoulos; M. V., Dhodapkar; J., Mccoy; J., Crowley; E. M., Ocio; R., Garcia Sanz; S. P., Treon; V., Leb...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
none
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/149523
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 341
  • ???jsp.display-item.citation.isi??? 283
social impact